[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526764":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":43,"responsibleParty":78,"collaborators":80,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":26,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"ETH Zurich","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention arm: Pharmacoscopy-guided clinical standard-of-care","EXPERIMENTAL","Patients in the PCY-guided treatment arm will receive one of the clinical standard-of-care treatments suggested by their own PCY results, and confirmed by the treating physician.",[13],"Diagnostic Test: Pharmacoscopy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","ACTIVE_COMPARATOR","Patients in the control arm will be treated with clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).",[19],"Drug: Clinical standard-of-care (physician's choice)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIAGNOSTIC_TEST","Pharmacoscopy","Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DRUG","Clinical standard-of-care (physician's choice)","Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).",[15],[33],{"name":34,"affiliation":35,"role":36},"Alexandre Theocharides, MD PhD","University of Zurich","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":26,"email":42},"Berend Snijder, PhD","CONTACT","+41 44 633 71 49","bsnijder@ethz.ch",[44,63],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Inselspital Bern","RECRUITING","Bern","Canton of Bern","3010","Switzerland","CH",{"type":53,"coordinates":54},"Point",[55,56],7.44744,46.94809,{"lat":56,"lon":55},[59],{"name":60,"role":40,"phone":61,"phoneExt":26,"email":62},"Thomas Pabst, Prof. Dr. med","+41 31 632 41 14","Thomas.Pabst@insel.ch",{"facility":64,"status":46,"city":65,"state":66,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"University Hospital Zurich","Zurich","Canton of Zurich","8091",{"type":53,"coordinates":69},[70,71],8.55,47.36667,{"lat":71,"lon":70},[74],{"name":75,"role":40,"phone":76,"phoneExt":26,"email":77},"Alexandre Theocharides, Prof. Dr. med","+41 44 255 37 82","alexandre.theocharides@usz.ch",{"type":79,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[81,82],{"name":35,"class":6},{"name":83,"class":6},"Insel Gruppe AG, University Hospital Bern","100526764","phase-2-pharmacoscopy-guided-clinical-standard-of-care-in-rr-aml-100526764",false,"NCT06138990","Pharmacoscopy-guided Clinical Standard-of-care in r\u002Fr AML","Pharmacoscopy-guided Clinical Standard-of-care in Relapsed\u002FRefractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial","RAPID-01","Inclusion criteria\n\n* Patient with refractory or relapsed AML according to ELN2022 criteria.\n* Age 18-70 years.\n* Considered to be eligible for intensive chemotherapy.\n* Written informed consent.\n\nExclusion criteria\n\n* Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes\u002Fchromosome translocations.\n* Blast crisis after chronic myeloid leukemia (CML).\n* Considered not eligible for intensive chemotherapy.\n* Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment).\n* PCY not working \u002F patient sample did not pass the QC steps of PCY.\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the principal investigator may interfere with the project or affect patient compliance.\n* Legal incompetence or Subjects lacking capacity to provide informed consent.\n* Participation in a clinical trial with an investigational drug within the 30 days preceding and during the present investigation.","ALL","18 Years","70 Years",{"count":96,"type":97},88,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","With an overall survival of below 12 months, the outcome of relapsed\u002Frefractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed\u002Frefractory AML.",[103],"AML, Adult",[105,23,106],"relapsed \u002F refractory AML","Functional precision medicine","2025-05-13",{"date":109,"type":110},"2025-05-16","ACTUAL",{"date":112,"type":110},"2024-09-02",{"date":114,"type":97},"2026-06-30",{"name":5,"class":6},2]